Solid Biosciences doses first patient in Phase 3 trial of gene therapy SGT-003 for Duchenne muscular dystrophy

Solid Biosciences has dosed the first participant in its Phase 3 IMPACT DUCHENNE trial, testing the gene therapy SGT-003 for Duchenne muscular dystrophy. This placebo-controlled, randomized, double-blind study aims to provide robust data to support regulatory approval globally. The therapy has shown good safety in earlier trials, with 46 participants dosed and no serious adverse effects reported. The trial is a key step toward offering a new treatment option for this severe genetic muscle disease, with sites active in multiple countries and further expansions planned.